Interferon and Interleukin — The Older Immunotherapies

They were the first immunotherapies. From the 1980s, interferon and interleukin-2 were given for advanced melanoma, advanced kidney cancer, some leukaemias and lymphomas and a few rarer tumours. They were used because, at the time, almost nothing else acted on the immune system at all.

Both are cytokines — the signalling proteins your immune system uses to raise an alarm. They are made in the laboratory and given as a drug, at doses far above anything the body produces on its own.

Interferon was an injection, often continuing for months. It was used after surgery for melanoma, in hairy cell leukaemia, in chronic myeloid leukaemia before targeted tablets arrived, and in some lymphomas and neuroendocrine tumours. Interleukin-2 was different: given at high dose, inside hospital, with close monitoring, for advanced melanoma and advanced kidney cancer.

This page names cytokine classes only. It carries no brand or product names, makes no claim about how well any of these treatments worked, and compares no product against another. Guideline and availability positions are written as understood in August 2026 and should be confirmed with your treating oncologist.

Status as understood in August 2026, following NCCN, ESMO and CDSCO patient-education framing. Guideline positions and marketing status both change over time — confirm the current position with your treating oncologist before acting on anything in this table.

None of that is a reason to refuse the immunotherapy being offered now, because it is not what that treatment usually feels like. A checkpoint infusion is short day-care treatment, repeated every two to six weeks, and most patients carry on with ordinary life between cycles. Immune-related side effects can still occur, and some of them are serious, so anything new is reported to your treating team the same day — but the everyday experience is not comparable.

Classes and mechanisms only — no product names, no efficacy figures and no comparison of how well one treatment works against another. Eligibility for any of this is a specialist decision made on your own diagnosis, stage and test results.

1. 1

   Ask which class of drug is planned, in writing

   Not just “immunotherapy”. Ask your oncologist to write down whether it is a checkpoint inhibitor, a cytokine, an antibody, a bispecific or a cell therapy. That single line answers most of the family's fear.

2. 2

   Ask where it is given, and for how long

   Day care and admission are not the same thing, and an admission is not automatically a sign of toxicity. Some newer treatments need a planned hospital stay for the first doses purely for observation — Step-Up Dosing and Hospital Admission for Bispecific Therapy explains one example.

3. 3

   Ask what to watch for, and who to call

   Immune-related side effects behave differently from the flu-like reaction of cytokine therapy. They can appear weeks or months after a dose, so get the warning list and the contact number before cycle one, and use it the same day rather than waiting for the next appointment. The CION helpline is 1800 202 8726.

4. 4

   Bring the relative to the consultation

   The fear is usually specific — a memory of injections, of a hospital stay, of someone who could not get out of bed. It is easier to answer in the room than over the phone, and a family that understands the plan is a family that keeps the plan running.

• BCG Bladder Instillation: What the Treatment Involves — the oldest immunotherapy of them all, and one that is still standard treatment in India rather than superseded.
• Donor Lymphocyte Infusion After Transplant — another long-established immune approach, used only inside transplant programmes, and referred rather than given at CION.
• Step-Up Dosing and Hospital Admission for Bispecific Therapy — why a modern treatment can still need a planned admission, and why that is about observation rather than toxicity.
• Immunotherapy at CION Cancer Clinics — the hub page, covering the immunotherapy that is standard treatment in India today: eligibility, biomarker testing, day-care administration and cost.

This page is general information and does not replace a consultation. It names cytokine classes and mechanisms only, not products, and makes no efficacy claim or comparison. Guideline positions and Indian marketing status are stated as understood in August 2026 and change over time — verify the current position with CDSCO and with your treating oncologist before making any decision.

Families ask us this almost every week

Someone in the family remembers interferon, and assumes the new treatment will be the same. It usually is not. Our team will take the time to explain the difference before anything starts.